© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Laura J. Esserman, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.
Laura J. Esserman, MD, professor, Departments of Surgery and Radiology, affiliate faculty, Institute for Health Policy Studies, University of California, San Francisco, director, Carol Franc Buck Breast Care Center; co-leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.